Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 8:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 605 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Kidney Functional Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function

NCT00824590
View directory record Official record
Conditions
Alzheimer's Disease, Huntington's Disease
Interventions
Dimebon
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
Miami, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 30, 2009 · Synced Oct 25, 2026, 8:55 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Human B-type Natriuretic Peptide (BNP) (Nesiritide) to Help Heart, Kidney, and Hormonal Functions in Persons With Lower Heart Pumping Function

NCT00405639
View directory record Official record
Conditions
Heart Failure, Asymptomatic Systolic Dysfunction
Interventions
Nesiritide, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Oct 25, 2026, 8:55 PM EDT
Completed No phase listed Observational

Adipose Tissue Function After Pancreas Transplantation

NCT01729130
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, End Stage Renal Disease
Interventions
Adipose tissue biopsy
Procedure
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 25, 2026, 8:55 PM EDT
Completed Not applicable Interventional

Pomegranate Supplementation on Physical Function and Cardiovascular Disease Risk in CKD Patients

NCT01324193
View directory record Official record
Conditions
Chronic Kidney Disease, Cardiovascular Disease
Interventions
Pomegranate extracts
Dietary Supplement
Lead sponsor
Kenneth Wilund
Other
Eligibility
30 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Champaign, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Oct 25, 2026, 8:55 PM EDT
Completed Phase 2 Interventional Results available

A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure

NCT02157506
View directory record Official record
Conditions
Heart Failure, Decompensated Heart Failure, Acute Heart Failure
Interventions
CXL-1427, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
14
States / cities
Gainesville, Florida • Jacksonville, Florida • Macon, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 25, 2026, 8:55 PM EDT
Recruiting Early Phase 1 Interventional

SMART 2D: Study of Montelukast's Effects on Renal and Cardiovascular Health in Adolescents and Young Adults With Type 2 Diabetes

NCT07409714
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Montelukast, Montelukast Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
14 Years to 24 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 25, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function

NCT01761773
View directory record Official record
Conditions
Healthy, Renal Impairment
Interventions
cabozantinib
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 25, 2026, 8:55 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Sympatholysis in Chronic Kidney Disease

NCT02411773
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Sodium Bicarbonate, Placebo, Exercise Training, Control to Exercise (Stretching)
Drug · Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 25, 2026, 8:55 PM EDT
Completed Not applicable Interventional Results available

Home-Based Exercise to Treat Decreased Physical Function in Patients With Varying Levels of Kidney Function

NCT04745169
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
8 week home-based exercise program
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 25, 2026, 8:55 PM EDT
Completed Early Phase 1 Interventional Results available

Bicarbonate Administration and Cognitive Function in Midlife and Older Adults With CKD

NCT04600323
View directory record Official record
Conditions
Metabolic Acidosis, Chronic Kidney Disease, Cognitive Dysfunction
Interventions
Sodium Bicarbonate Tablets, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 25, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901

NCT02975388
View directory record Official record
Conditions
Renal Impairment
Interventions
RO7079901
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
5
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 25, 2026, 8:55 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease

NCT07168356
View directory record Official record
Conditions
Hepatitis B
Interventions
Bepirovirsen
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Orlando, Florida • Tampa, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 25, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment

NCT01830205
View directory record Official record
Conditions
Hepatitis C
Interventions
Daclatasvir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Oct 25, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Elinzanetant Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Kidneys That do Not Work as Well as They Should Compared to Participants Whose Kidneys Work Normally

NCT05071729
View directory record Official record
Conditions
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
Interventions
Elinzanetant (BAY3427080)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 25, 2026, 8:55 PM EDT
Completed No phase listed Observational

New Non-invasive Methods for Real-time Monitoring of Organ Function.

NCT00851851
View directory record Official record
Conditions
Acute Renal Failure, Chronic Renal Failure
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
641 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Oct 25, 2026, 8:55 PM EDT
Completed No phase listed Observational

Mapping of End Stage Renal Disease Genetic Susceptibility in African Americans by Admixture Linkage Disequilibrium

NCT00559767
View directory record Official record
Conditions
End Stage Renal Disease (ESRD)
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
21 Years and older
Enrollment
2,860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 8:55 PM EDT
Completed No phase listed Observational

Biomarkers of Renal Dysfunction in Neuroblastoma Survivors

NCT03947346
View directory record Official record
Conditions
Neuroblastoma Survivors
Interventions
Urine sample
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Up to 20 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 25, 2026, 8:55 PM EDT
Completed Phase 2 Interventional Results available

Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function

NCT00478361
View directory record Official record
Conditions
Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer
Interventions
Gemcitabine hydrochloride, Paclitaxel, Doxorubicin hydrochloride, Pegfilgrastim
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
2
States / cities
Springfield, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2020 · Synced Oct 25, 2026, 8:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study to Evaluate if the Drug Vasopressin Protects the Kidneys for Patients Undergoing Liver Transplant

NCT00886262
View directory record Official record
Conditions
Liver Failure
Interventions
Vasopressin, Normal saline placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 25, 2026, 8:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function

NCT03618420
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Nephropathy, Diabetic Nephropathies, Juvenile Diabetes, Diabetes Mellitus Complication, Autoimmune Diabetes, Type 1 Diabetes Mellitus
Interventions
Aminohippurate Sodium Inj 20%, Iohexol Inj 300 mg/mL
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 25, 2026, 8:55 PM EDT
Recruiting Phase 2 Interventional

Equol and Vascular Function in Women With Chronic Kidney Disease

NCT07194590
View directory record Official record
Conditions
Chronic Kidney Disease (Stage 3-4), Vascular Function, Cognitive Functions, Cerebrovascular Function, Blood Pressure
Interventions
Equol, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years and older · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 25, 2026, 8:55 PM EDT
Completed Not applicable Interventional Results available

Pedometers to Assess and Increase Physical Activity Among Children With Chronic Kidney Disease

NCT01270529
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Increasing Physical activity
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
6 Years to 20 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Oct 25, 2026, 8:55 PM EDT
Completed Phase 3 Interventional Results available

A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes

NCT02017171
View directory record Official record
Conditions
Diabetic Nephropathies, Coronary Artery Disease
Interventions
Allopurinol, Placebo
Drug
Lead sponsor
Alessandro Doria
Other
Eligibility
18 Years to 70 Years
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
23
States / cities
Aurora, Colorado • Denver, Colorado • Atlanta, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 25, 2026, 8:55 PM EDT
Completed Phase 2 Interventional Results available

Metabolic Effects of Paricalcitol

NCT01003275
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Paricalcitol, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Oct 25, 2026, 8:55 PM EDT